Screener / SEC EDGAR /CIK 0002019410 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Labs

Caris Life Sciences, Inc. CAI

Compare with peers Embed

CAI among the 162 companies we cover

Where it stands · the better end on the right. The band holds the middle half; the line is the median.

All 162
Sales growth
+4.8%+20.2%
+97.0%7th of 155 · median +10.5%
Net margin
-4.1%15.3%
9.2%67th of 154 · median 6.8%
Return on equity
-5.2%18.5%
15.0%49th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
2.8%108th of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
0.6148th of 108 · median 0.69

CAI and 9 peers, year by year

The 9 Health care companies closest to CAI in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.

Choose the peers

Health care companies (up to 9):

Each company's latest fiscal year
CompanyYearRevenueSales growthGross marginOperating marginNet marginFCF marginReturn on equityDebt / equity
CAI Caris Life Sciences, Inc. FY2025 $812.0M+97.0%-5.6%−8.4%8.2%−11.8%0.66
CORT Corcept Therapeutics Inc FY2025 $761.4M+12.8%-5.9%13.1%18.6%15.4%-
BCRX Biocryst Pharmaceuticals Inc FY2025 $874.8M+94.1%-39.0%30.2%39.4%n/mn/m
IONS Ionis Pharmaceuticals Inc FY2025 $943.7M+33.8%-−40.4%−40.4%−33.9%−78.0%3.71
BBIO BridgeBio Pharma, Inc. FY2025 $502.1M+126%-−104.2%−144.4%−89.0%n/mn/m
WRBY Warby Parker Inc. FY2025 $871.9M+13.0%54.0%−0.6%0.2%5.0%0.4%-
PBH Prestige Consumer Healthcare Inc. FY2026 $1.1B−4.3%54.7%28.4%17.5%22.6%10.1%0.53
TGTX TG Therapeutics, Inc. FY2025 $616.3M+87.3%-20.0%72.6%−4.1%69.0%0.38
ACAD Acadia Pharmaceuticals Inc FY2025 $1.1B+11.9%-9.8%36.5%9.8%31.9%-
INSP Inspire Medical Systems, Inc. FY2025 $912.0M+13.6%85.4%5.6%15.9%8.6%18.6%-

Each company, year by year

Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2023 to FY2025 · 10-K XBRL

CAICaris Life Sciences, Inc.
FY2023 revenue $306.1MFY2024 revenue $412.3MFY2025 revenue $812.0M FY2023 net margin −111.5%FY2024 net margin −68.4%FY2025 net margin −8.4% FY2023FY2025
Revenue$812.0M Growth+97.0% Net margin−8.4%
CORTCorcept Therapeutics Inc
FY2023 revenue $482.4MFY2024 revenue $675.0MFY2025 revenue $761.4M FY2023 net margin 22.0%FY2024 net margin 20.9%FY2025 net margin 13.1% FY2023FY2025
Revenue$761.4M Growth+12.8% Net margin13.1%
BCRXBiocryst Pharmaceuticals Inc
FY2023 revenue $331.4MFY2024 revenue $450.7MFY2025 revenue $874.8M FY2023 net margin −68.4%FY2024 net margin −19.7%FY2025 net margin 30.2% FY2023FY2025
Revenue$874.8M Growth+94.1% Net margin30.2%
IONSIonis Pharmaceuticals Inc
FY2023 revenue $787.6MFY2024 revenue $705.1MFY2025 revenue $943.7M FY2023 net margin −46.5%FY2024 net margin −64.4%FY2025 net margin −40.4% FY2023FY2025
Revenue$943.7M Growth+33.8% Net margin−40.4%
BBIOBridgeBio Pharma, Inc.
FY2023 revenue $9.3MFY2024 revenue $221.9MFY2025 revenue $502.1M FY2024 net margin −241.4%FY2025 net margin −144.4% FY2023FY2025
Revenue$502.1M Growth+126% Net margin−144.4%
WRBYWarby Parker Inc.
FY2023 revenue $669.8MFY2024 revenue $771.3MFY2025 revenue $871.9M FY2023 net margin −9.4%FY2024 net margin −2.6%FY2025 net margin 0.2% FY2023FY2025
Revenue$871.9M Growth+13.0% Net margin0.2%
PBHPrestige Consumer Healthcare Inc.
FY2023 revenue $1.1BFY2024 revenue $1.1BFY2025 revenue $1.1B FY2023 net margin −7.3%FY2024 net margin 18.6%FY2025 net margin 18.9% FY2023FY2025
Revenue$1.1B Growth+1.1% Net margin18.9%
TGTXTG Therapeutics, Inc.
FY2023 revenue $233.7MFY2024 revenue $329.0MFY2025 revenue $616.3M FY2023 net margin 5.4%FY2024 net margin 7.1%FY2025 net margin 72.6% FY2023FY2025
Revenue$616.3M Growth+87.3% Net margin72.6%
ACADAcadia Pharmaceuticals Inc
FY2023 revenue $726.4MFY2024 revenue $957.8MFY2025 revenue $1.1B FY2023 net margin −8.4%FY2024 net margin 23.6%FY2025 net margin 36.5% FY2023FY2025
Revenue$1.1B Growth+11.9% Net margin36.5%
INSPInspire Medical Systems, Inc.
FY2023 revenue $624.8MFY2024 revenue $802.8MFY2025 revenue $912.0M FY2023 net margin −3.4%FY2024 net margin 6.7%FY2025 net margin 15.9% FY2023FY2025
Revenue$912.0M Growth+13.6% Net margin15.9%

Who rewrote the most

Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before

Risk FactorsMD&AEach company's latest 10-K, so the dates differ. A company that rewrote much may have reorganized the text.

Revenue, FY2023 to FY2025

Revenue as reported in the 10-K.

100 500 2000 FY2023FY2024FY2025 CORT: $482.4M, $675.0M, $761.4M CORT BCRX: $331.4M, $450.7M, $874.8M BCRX IONS: $787.6M, $705.1M, $943.7M IONS BBIO: $9.3M, $221.9M, $502.1M BBIO WRBY: $669.8M, $771.3M, $871.9M WRBY PBH: $1.1B, $1.1B, $1.1B PBH TGTX: $233.7M, $329.0M, $616.3M TGTX ACAD: $726.4M, $957.8M, $1.1B ACAD INSP: $624.8M, $802.8M, $912.0M INSP CAI: $306.1M, $412.3M, $812.0M CAI
CAI is the bold green line; each peer has its own colour and dash, named at the line's end. Each company's first year in the window is 100, on a log scale: a line twice as high has doubled. A gap is a year with no number.

Sales growth, FY2023 to FY2025

Revenue against the fiscal year before.

−88.0% +126% FY2023FY2024FY2025 CORT: +20.0%, +39.9%, +12.8% CORT BCRX: +22.4%, +36.0%, +94.1% BCRX IONS: +34.1%, −10.5%, +33.8% IONS BBIO: −88.0%, n/m, +126% BBIO WRBY: +12.0%, +15.2%, +13.0% WRBY PBH: +3.8%, −0.2%, +1.1% PBH TGTX: n/m, +40.8%, +87.3% TGTX ACAD: +40.4%, +31.8%, +11.9% ACAD INSP: +53.2%, +28.5%, +13.6% INSP CAI: -, +34.7%, +97.0% CAI
CAI is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −88.0% to +126%. A gap is a year with no number. A ring marks where a line starts: CAI, TGTX have no earlier 10-K here.

Gross margin, FY2023 to FY2025

Gross profit / revenue.

54.0% 94.3% FY2023FY2024FY2025 WRBY: 54.5%, 55.3%, 54.0% WRBY PBH: 55.4%, 55.5%, 55.8% PBH ACAD: 94.3%, -, - ACAD INSP: 84.5%, 84.7%, 85.4% INSP
CAI is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from 54.0% to 94.3%. A gap is a year with no number.
CompanyFY2023FY2024FY2025
CAI Dec ---
CORT Dec ---
BCRX Dec ---
IONS Dec ---
BBIO Dec ---
WRBY Dec 54.5%55.3%54.0%
PBH Mar 55.4%55.5%55.8%
TGTX Dec ---
ACAD Dec 94.3%--
INSP Dec 84.5%84.7%85.4%
Peer median70.0%55.5%55.8%

Operating margin, FY2023 to FY2025

Operating income / revenue.

−267.2% 39.0% FY2023FY2024FY2025 CORT: 22.2%, 20.3%, 5.9% CORT BCRX: −31.3%, −0.6%, 39.0% BCRX IONS: −44.9%, −67.4%, −40.4% IONS BBIO: n/m, −267.2%, −104.2% BBIO WRBY: −10.7%, −3.9%, −0.6% WRBY PBH: −2.0%, 30.4%, 29.6% PBH TGTX: 8.8%, 12.7%, 20.0% TGTX ACAD: −10.1%, 24.1%, 9.8% ACAD INSP: −6.4%, 4.5%, 5.6% INSP CAI: −104.4%, −62.4%, 5.6% CAI
CAI is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −267.2% to 39.0%. A gap is a year with no number. A ring marks where a line starts: BBIO has no earlier 10-K here.

Net margin, FY2023 to FY2025

Net income / revenue.

−241.4% 72.6% FY2023FY2024FY2025 CORT: 22.0%, 20.9%, 13.1% CORT BCRX: −68.4%, −19.7%, 30.2% BCRX IONS: −46.5%, −64.4%, −40.4% IONS BBIO: n/m, −241.4%, −144.4% BBIO WRBY: −9.4%, −2.6%, 0.2% WRBY PBH: −7.3%, 18.6%, 18.9% PBH TGTX: 5.4%, 7.1%, 72.6% TGTX ACAD: −8.4%, 23.6%, 36.5% ACAD INSP: −3.4%, 6.7%, 15.9% INSP CAI: −111.5%, −68.4%, −8.4% CAI
CAI is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −241.4% to 72.6%. A gap is a year with no number. A ring marks where a line starts: BBIO has no earlier 10-K here.

Free cash flow, FY2023 to FY2025

Cash from operations minus capital spending.

−$546.2M $344.9M FY2023FY2024FY2025 CORT: $126.5M, $196.1M, $141.8M CORT BCRX: −$97.3M, −$53.1M, $344.9M BCRX IONS: −$331.3M, −$546.2M, −$320.0M IONS BBIO: −$529.0M, −$521.7M, −$447.0M BBIO WRBY: $7.3M, $34.7M, $43.7M WRBY PBH: $221.9M, $239.4M, $243.3M PBH TGTX: −$31.4M, −$40.6M, −$25.0M TGTX ACAD: $16.7M, $157.2M, $105.1M ACAD INSP: $1.0M, $91.1M, $78.5M INSP CAI: −$298.4M, −$253.6M, $66.9M CAI
CAI is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$546.2M to $344.9M. A gap is a year with no number.

FCF margin, FY2023 to FY2025

Free cash flow / revenue.

−235.1% 39.4% FY2023FY2024FY2025 CORT: 26.2%, 29.1%, 18.6% CORT BCRX: −29.4%, −11.8%, 39.4% BCRX IONS: −42.1%, −77.5%, −33.9% IONS BBIO: n/m, −235.1%, −89.0% BBIO WRBY: 1.1%, 4.5%, 5.0% WRBY PBH: 19.7%, 21.3%, 21.4% PBH TGTX: −13.4%, −12.3%, −4.1% TGTX ACAD: 2.3%, 16.4%, 9.8% ACAD INSP: 0.2%, 11.4%, 8.6% INSP CAI: −97.5%, −61.5%, 8.2% CAI
CAI is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −235.1% to 39.4%. A gap is a year with no number. A ring marks where a line starts: BBIO has no earlier 10-K here.

Return on equity, FY2023 to FY2025

Net income / shareholders' equity at the year end.

−94.7% 69.0% FY2023FY2024FY2025 CORT: 20.9%, 20.8%, 15.4% CORT IONS: −94.7%, −77.1%, −78.0% IONS WRBY: −20.9%, −6.0%, 0.4% WRBY PBH: −5.7%, 12.6%, 11.7% PBH TGTX: 7.9%, 10.5%, 69.0% TGTX ACAD: −14.2%, 30.9%, 31.9% ACAD INSP: −3.7%, 7.8%, 18.6% INSP CAI: n/m, n/m, −11.8% CAI
CAI is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −94.7% to 69.0%. A gap is a year with no number. A ring marks where a line starts: CAI has no earlier 10-K here.

Debt / equity, FY2023 to FY2025

Total debt / shareholders' equity at the year end.

0.38 3.71 FY2023FY2024FY2025 IONS: 3.38, 2.13, 3.71 IONS PBH: 0.93, 0.68, 0.54 PBH TGTX: 0.63, 1.10, 0.38 TGTX CAI: -, n/m, 0.66 CAI
CAI is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from 0.38 to 3.71. A gap is a year with no number. A ring marks where a line starts: CAI has no earlier 10-K here.
CompanyFY2023FY2024FY2025
CAI Dec -n/m0.66
CORT Dec ---
BCRX Dec n/mn/mn/m
IONS Dec 3.382.133.71
BBIO Dec n/mn/mn/m
WRBY Dec ---
PBH Mar 0.930.680.54
TGTX Dec 0.631.100.38
ACAD Dec ---
INSP Dec ---
Peer median0.931.100.54

EPS (diluted), FY2023 to FY2025

Diluted earnings per share, on today's share count after splits.

−$13.24 $4.89 FY2023FY2024FY2025 CORT: $0.94, $1.23, $0.82 CORT BCRX: −$1.18, −$0.43, $1.21 BCRX IONS: −$2.56, −$3.04, −$2.38 IONS BBIO: −$3.95, −$2.88, −$3.78 BBIO WRBY: −$0.54, −$0.17, $0.01 WRBY PBH: −$1.65, $4.17, $4.29 PBH TGTX: $0.09, $0.15, $2.77 TGTX ACAD: −$0.37, $1.36, $2.30 ACAD INSP: −$0.72, $1.75, $4.89 INSP CAI: −$13.24, −$10.66, −$3.22 CAI
CAI is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$13.24 to $4.89. A gap is a year with no number.

Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out CAI and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more

Sources

Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.

Also

Financials: CAI's own statements, year by year. Compare: the whole peer group on one page.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CAI/export.csv") into a cell.

Next:Industry numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.